C12N 2320/52
Modulating the physical stability
Official title: modulating the physical stability, e.g. GC-content
C12N2320/52 (Modulating the physical stability) appears on 97 US grants and 155 published applications in this corpus.
Search patents in C12N- Granted patents
- 97
- Published applications
- 155
- Assignees
- 78
- Inventors
- 257
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 3 |
| 2011 | 0 | 3 |
| 2012 | 1 | 5 |
| 2013 | 4 | 7 |
| 2014 | 6 | 11 |
| 2015 | 2 | 13 |
| 2016 | 9 | 5 |
| 2017 | 11 | 10 |
| 2018 | 6 | 15 |
| 2019 | 8 | 11 |
| 2020 | 8 | 7 |
| 2021 | 12 | 12 |
| 2022 | 5 | 11 |
| 2023 | 5 | 14 |
| 2024 | 5 | 8 |
| 2025 | 12 | 9 |
| 2026 | 2 | 9 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Light-inducible CRISPR/Cas9 system for genome editing28 Apr 2026US 12,612,624 B2The Johns Hopkins University
- Double-stranded nucleic acid inhibitor molecules with shortened sense strands20 Jan 2026US 12,529,053 B2Novo Nordisk A/S
- Artificial nucleic acid molecules for improved protein or peptide expression4 Nov 2025US 12,460,204 B2CureVac AG
- Hybrid htiRNA/nanoparticle complex and use thereof for treating a disease of the digestive system14 Oct 2025US 12,441,999 B2Commissariat A L' Energie Atomique Et Aux Energies Alternatives
- Nucleoside derivative and use thereof26 Aug 2025US 12,398,170 B2National University Corporation Tokai National Higher Education and Research System
- Formulations of nucleic acid compounds and uses thereof27 Aug 2026US 2026/0248839 A1Comanche Biopharma Corp.
- Modified guide rna for reducing off-target editing30 Jul 2026US 2026/0218173 A1Integrated Dna Technologies, Inc.
- Chemically Modified saRNA Compositions and Methods of Use30 Jul 2026US 2026/0218178 A1Mina Therapeutics Limited
- Compositions and methods for modifying a target nucleic acid25 Jun 2026US 2026/0176604 A1The Regents of the University of California
- Prime Editing Systems having pegRNA with Reduced Auto-inhibitory Interaction30 Apr 2026US 2026/0117214 A1University of Massachusetts
Most cited
By later US patents
- Extended dicer substrate agents and methods for the specific inhibition of gene expression113US 8,513,207 B2Dicerna Pharmaceuticals, Inc. · 2013
- Modified iRNA agents105US 9,290,760 B2Alnylam Pharmaceuticals, Inc. · 2016
- Artificial nucleic acid molecules for improved protein or peptide expression61US 9,683,233 B2CureVac AG · 2017
- RNA interference in dermal and fibrotic indications51US 9,340,786 B2RXi Pharmaceuticals Corporation · 2016
- Artificial nucleic acid molecules for improved protein or peptide expression38US 10,738,306 B2CureVac AG · 2020